Effect of peritoneal dialysis solution type on serum lipid levels in end-stage renal disease
- PMID: 17497445
- DOI: 10.1080/08860220601166545
Effect of peritoneal dialysis solution type on serum lipid levels in end-stage renal disease
Abstract
Among the different cardiovascular risk factors, lipid abnormalities dominate the high mortality in chronic ambulatory peritoneal dialysis patients. So far, no data comparing the effect of standard glucose-containing, amino acid-containing, and icodextrin-containing peritoneal dialysis solutions on serum lipid concentrations in a chronic ambulatory peritoneal dialysis population are available. To determine the effect of peritoneal dialysis solutions on parameters of lipid metabolism, 67 subjects who had continued their usual dialysis for the last six months were enrolled in the study. Group A consisted of 18 patients who were receiving only glucose-based peritoneal dialysis solutions, group B consisted of 18 patients who were receiving glucose and amino acid-based peritoneal dialysis solutions, and group C consisted of 31 patients who were receiving glucose and icodextrin-based peritoneal dialysis solutions. Serum lipid parameters including total cholesterol, low-density lipoprotein, high-density lipoprotein, triglyceride, and lipoprotein (a) were determined in all groups. No significant difference in serum lipid parameters was found between groups A, B, and C. These results demonstrate the lack of the effect of amino acid or icodextrin-based peritoneal solutions on dyslipidemia of CAPD patients.
Similar articles
-
Icodextrine and insulin resistance in continuous ambulatory peritoneal dialysis patients.Ren Fail. 2007;29(3):289-93. doi: 10.1080/08860220601166271. Ren Fail. 2007. PMID: 17497442
-
The effect of icodextrin and glucose-containing solutions on insulin resistance in CAPD patients.Clin Nephrol. 2006 Oct;66(4):263-8. doi: 10.5414/cnp66263. Clin Nephrol. 2006. PMID: 17063993
-
Glucose concentration in the dialysate does not contribute to lipid profiles in patients undergoing CAPD.Ren Fail. 2011;33(2):124-30. doi: 10.3109/0886022X.2010.541580. Ren Fail. 2011. PMID: 21332332
-
Evidence-based medicine in peritoneal dialysis: peritoneal dialysis solutions.Contrib Nephrol. 2003;(140):202-8. doi: 10.1159/000071392. Contrib Nephrol. 2003. PMID: 12800361 Review. No abstract available.
-
Adverse effects of systemic glucose absorption with peritoneal dialysis: how good is the evidence?Curr Opin Nephrol Hypertens. 2013 Nov;22(6):663-8. doi: 10.1097/MNH.0b013e328365b3d1. Curr Opin Nephrol Hypertens. 2013. PMID: 24076559 Review.
Cited by
-
Complications of Peritoneal Dialysis Part II: Nonmechanical Complications.Clin J Am Soc Nephrol. 2024 Jun 1;19(6):791-799. doi: 10.2215/CJN.0000000000000418. Epub 2024 Jan 8. Clin J Am Soc Nephrol. 2024. PMID: 38190143 Free PMC article. Review.
-
Biphasic Regulation of Lipid Metabolism: A Meta-Analysis of Icodextrin in Peritoneal Dialysis.Biomed Res Int. 2015;2015:208980. doi: 10.1155/2015/208980. Epub 2015 Dec 15. Biomed Res Int. 2015. PMID: 26788499 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical